Impressive write-up, thanks. And timely! Personally slightly disappointed they connected with Coors, bit down-market compared with them - would have preferred a tie-up with a similar high-end brand.
Lucky! Ya, bit of an odd choice from my perspective. I don't love the issuance at the current price but if it helps scale the US it could still be a home run.
No their end customers don't have a high switching cost but they can still have scale advantages in buying ingredients, sourcing, and brand building activities. I'm not sure I fully understand this comment
Impressive write-up, thanks. And timely! Personally slightly disappointed they connected with Coors, bit down-market compared with them - would have preferred a tie-up with a similar high-end brand.
Lucky! Ya, bit of an odd choice from my perspective. I don't love the issuance at the current price but if it helps scale the US it could still be a home run.
Even after the move the stock is cheap IMO.
Excellent pitch.
Fever-Tree was the first addition to our NED Index!
Back in October of ‘24:
https://www.philoinvestor.com/s/no-end-dividend
Does FeverTree have high switching cost? if the answer is NO. then the scale advantage does not exist.
No their end customers don't have a high switching cost but they can still have scale advantages in buying ingredients, sourcing, and brand building activities. I'm not sure I fully understand this comment